Statements (23)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:activeIngredient |
efmoroctocog alfa
|
| gptkbp:approvalYear |
2015
|
| gptkbp:approvedBy |
gptkb:European_Union
gptkb:United_States |
| gptkbp:ATCCode |
B02BD02
|
| gptkbp:brand |
gptkb:Eloctate
|
| gptkbp:developedBy |
gptkb:Biogen
Swedish Orphan Biovitrum |
| gptkbp:drugClass |
antihemorrhagic agent
|
| gptkbp:form |
powder and solvent for solution for injection
|
| gptkbp:halfLife |
long-acting
|
| https://www.w3.org/2000/01/rdf-schema#label |
Elocta
|
| gptkbp:indication |
perioperative management in hemophilia A
prevention of bleeding in hemophilia A treatment of bleeding in hemophilia A |
| gptkbp:legalStatus |
prescription only
|
| gptkbp:marketingAuthorizationHolder |
Swedish Orphan Biovitrum
|
| gptkbp:mechanismOfAction |
recombinant factor VIII Fc fusion protein
|
| gptkbp:routeOfAdministration |
intravenous
|
| gptkbp:usedFor |
gptkb:hemophilia_A
|
| gptkbp:bfsParent |
gptkb:Sobi
|
| gptkbp:bfsLayer |
7
|